Gemin X Pharmaceuticals develops and commercializes targeted cancer therapeutics to improve the lives of patients.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.
Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 24, 2010 | Series E | $8M | 1 | Caxton Advantage Life Sciences Fund | — | Detail |
Apr 20, 2010 | Series D | $16M | 1 | Caxton Advantage Life Sciences Fund | — | Detail |
Jul 3, 2008 | Series C | $38M | 3 | Caxton Advantage Life Sciences Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Caxton Advantage Life Sciences Fund | Yes | Series E |
Canadian Medical Discoveries Fund | — | Series C |
SB Life Science | — | Series C |